Patent Application
20230355506
The present application claims priority under 35 U.S.C. § 119 of European Patent Application 22171536.0, filed May 4, 2022, the entire disclosure of which is expressly incorporated by reference herein.
The present invention relates to an active ingredient complex for a cosmetic preparation.
A known nuisance for many women and men is that the skin, in particular the skin of the face, loses volume and firmness with increasing age. As a consequence, in some circumstances, the contours of the face may visibly change. One result is the undesired formation of wrinkles.
The market offers a large number of cosmetic active ingredients and preparations which on repeated daily application to the skin lead to a reduction in the depth of wrinkles. However, a fundamental understanding of the skin structure is crucial for the effective treatment of wrinkles.
Tissues consist primarily of two different elements: living cells and the extracellular matrix. The extracellular matrix (ECM) functions as a kind of filler material lying between the otherwise densely packed cells. The ECM known as connective tissue can also serve to connect tissues such as the skin and muscles.
The ECM is a complex structure consisting of various proteins, proteoglycans and polysaccharides that provides a framework for cells, retains water and modulates biological processes such as cell adhesion, migration, repair, survival and development.
The role of the ECM in cell adhesion and signal transduction into the cells is performed by integrins, which transduce signals through the cell membrane in order to activate intracellular signal transduction. This crosstalk between the ECM and the cells regulates many cellular activities that are important for maintaining homeostasis of the tissue.
In the skin, the ECM forms a specific structure consisting of thick horizontal and vertical elements and a network-like fine structure in-between which structures the spatial distribution of the skin cells in the various layers (epidermis, dermis and hypodermis).
The retinacula cutis are connective tissue strands that pervade through the subcutis and anchor the skin to deeper-lying structures (periosteum, fasciae). They restrict the skin's movability. The retinacula cutis form a continuous network of fibrous extracellular matrix in the hypodermis. The fiber bundles consist of an aggregation of fibers that run more or less vertically from the outer layer of the deep fascia and form thin connections with the base of the dermis. Not all fibers extend over the full thickness of the hypodermis. Horizontal branches divide the hypodermis into two or three layers, also referred to as superficial fasciae. If blood vessels or nerves are present, the fibers of the skin ligaments form a fibrous sheath around these structures.
Between the fibers, a fine network of extracellular matrix elements serves to attach the cells of the adipose tissue, primarily adipocytes and preadipocytes, to the skin ligaments and acts as a framework that structures the spatial distribution of the cells.
Skin ligaments can be visualized in a very simplified manner as a tree, where the fibers represent the trunk and the thick branches of a tree and the fine network of ECM elements are all thin branches of a tree.
The fibers of the skin ligaments are primarily formed of collagen I and elastin, supplemented by proteoglycans such as mimecan, decorin, prolargin, lumican and biglycan.
The density and thickness of the skin ligaments (retinacula cutis) decreases with age. It has been found that the concentrations of key components of the ECM which form the skin ligaments, such as collagen I, collagen VI and mimecan, decrease with increasing age. This can in turn lead to the appearance of ageing phenomena such as sagging, wrinkles and losses of firmness and probably also of volume.
Accordingly, the literature contains a large number of attempts to promote the expression of collagen I. One known example is U.S. Pat. No. 7,279,329 B2.
However, the known attempts must not distract from the fact that there remains a need for particularly effective active ingredients and ingredient combinations that improve the expression of collagen I and thus reduce the appearance of ageing phenomena such as sagging, wrinkles and loss of firmness and volume.
Surprisingly, it has now been found that the expression of collagen I could be increased in a synergistic manner by means of the subject matter of the present invention.
The invention provides an active ingredient combination comprising
The invention also provides a cosmetic preparation comprising the active ingredient combination according to the invention.
The invention also provides for the use of the active ingredient combination in cosmetic preparations.
The invention also provides for the use of the active ingredient combination for increasing the expression of collagen I and for reducing skin ageing phenomena, in particular for reducing skin ageing phenomena such as sagging, wrinkles and loss of firmness and volume.
The invention further provides for the use of the active ingredient combination for reinforcing the skin ligaments or the retinacula cutis and/or the connective tissue strands in human skin. Reinforcement in this context means that the connective tissue strands become less tight and thus wearing out of the tissue is prevented.
The skin ligaments are also referred to as retinaculum cutis. The retinacula cutis are connective tissue strands that pervade through the subcutis and anchor the skin (cutis) to deeper-lying structures (periosteum, fasciae). They restrict the skin's movability.
The amplified expression of collagen I brings about a direct reinforcement of the skin ligaments, so that there is a reduction in skin ageing phenomena, such as sagging, wrinkles and loss of firmness and volume.
It was furthermore surprisingly found that the active ingredient combination of the invention also intensively promotes the expression of thrombospondin-1. Thrombospondin-1 is an adhesive protein which mediates cell-to-cell and cell-to-ECM interactions. In adipose tissue, it supports the anchorage of adipocytes to the skin ligaments. Consequently, it serves for the anchorage of constituents of the skin. An increased expression thus promotes the skin condition through improved anchorage of adipocytes to the skin ligaments.
All percentages by weight (% by weight) listed hereinafter are based, unless specified otherwise, in each case on the total weight of the cosmetic preparation. Where reference is made hereinafter to ratios, these refer, unless specified otherwise, to ratios by weight.
Unless specified otherwise, all experiments and process steps were conducted under normal conditions. The term “normal conditions” means 20° C., 1013 hPa and a relative humidity of 50%.
In the context of the present disclosure, the formulations “according to the invention”, “advantageous according to the invention”, “advantageous for the purposes of the present invention” etc. always relate to the active ingredient combination according to the invention, the preparation according to the invention and also to the use according to the invention.
Where the term skin is used hereinafter, this refers exclusively to human skin.
“Glycols” refers to those dialcohols (dihydric alcohols) that are derived from ethylene glycol (what are known as 1,2-diols or vicinal diols). Examples of these are ethylene glycol and propylene glycol.
According to the invention, the active ingredient combination comprises at least one caviar extract. Caviar extracts are declared in cosmetic products under the INCI name “Caviar Extract”.
Advantageously, the total content of caviar extract in the cosmetic preparation according to the invention is from 0.1% to 5% by weight, preferably 0.2% to 4% by weight and particularly preferably 0.5% to 3.5% by weight, based on the total weight of the preparation.
Caviar extracts are generally commercially available under various trade names. An example is Creanatural® Caviar Sevruga Extract, produced by The Innovation Company. Further caviar extracts can be commercially obtained from the Mibelle Biochemistry Group.
According to the invention, “caviar extract” is to be understood as meaning extracts of sturgeon fish eggs. Known, inter alia, are the Siberian sturgeon, the shortnose sturgeon, the Yangtze sturgeon, the lake sturgeon, the Russian sturgeon, the green sturgeon, the Sakhalin sturgeon, the Adriatic sturgeon, the ship sturgeon, Acipenser oxyrinchus, the Persian sturgeon, the sterlet, the Japanese sturgeon, the Chinese sturgeon, the starry sturgeon, the European sea sturgeon, the white sturgeon, the kaluga, and the beluga, which is often referred to as the beluga sturgeon. It should be noted here that a large number of sturgeon species are threatened with extinction, meaning that the use thereof should be avoided. Most preferably according to the invention, the fish eggs of the white sturgeon (Acipenser transmontanus) and/or of the Siberian sturgeon (Acipenser baerii) are chosen. The white sturgeon is classed as not threatened according to the IUCN (International Union for Conservation of Nature and Natural Resources).
It is particularly advantageous when exclusively fish eggs of farmed sturgeon, in particular of farmed Siberian and/or white sturgeon, are used to prepare the caviar extract. It is furthermore extremely preferable when the fish eggs are obtained by a method which is not lethal to the fish.
In general, the caviar extracts according to the invention may advantageously be prepared by a process comprising the steps of
Further purification steps are possible in general.
It is advantageous according to the invention when the active ingredient combination contains at least one caviar extract, in the preparation of which at least water and/or a glycol are added as solvent during the homogenization of the fish eggs and in which the aqueous phase is extracted to obtain the caviar extract.
It is advantageous according to the invention when at least one caviar extract is used which has the particular feature that in the preparation thereof at least water, but no glycol, or glycol in proportions by weight of water to glycol of 1.1:1.0 to 1000:1.0, is added as solvent during the homogenization of the fish eggs and in which the aqueous phase is extracted to obtain the caviar extract. This extract is referred to as hydrophilic caviar extract.
It is advantageous according to the invention when at least one caviar extract has the particular feature that in the preparation thereof at least glycol and optionally water are added as solvent during the homogenization of the fish eggs, where the proportions by weight of water to glycol are from 1.0:1.0 to 1.0:1000, and in which the glycolic phase is extracted to obtain the caviar extract. The glycolic phase is the phase that contains glycol. This extract is referred to as glycolic caviar extract.
It is furthermore advantageous according to the invention when the active ingredient combination contains at least one caviar extract, in the preparation of which at least oil is added as solvent during the homogenization of the fish eggs and in which the oil phase is extracted. Accordingly, an oil phase is obtained that contains the caviar extract.
Advantageously here, as oils, triglycerides are used, with particular preference being given to caprylic/capric triglyceride.
It is particularly advantageous to use at least two different caviar extracts, wherein a first lipophilic caviar extract is used, in the preparation of which at least oil, advantageously caprylic/capric triglyceride, is added as solvent during the homogenization of the fish eggs and in which the oil phase is extracted to obtain the extract, and wherein a second hydrophilic or glycolic caviar extract is used, in the preparation of which at least water and/or a glycol are added as solvent during the homogenization of the fish eggs and in which the aqueous phase is extracted to obtain the second extract.
It is furthermore particularly advantageous when three different caviar extracts are used, where
A glycolic phase is a phase including a glycol.
It is furthermore particularly advantageous when three different caviar extracts are used, where
As regards the lipophilic caviar extract, it is preferable when, in addition to the oil, which is advantageously caprylic/capric triglyceride, water is added during the homogenization. In this case, there is a separation of the lipophilic and hydrophilic constituents of the homogenizate. Correspondingly, predominantly lipophilic constituents of the homogenizate are extracted during the extraction of the oil phase. In this process it is advantageous when the added oils for homogenization contain at least caprylic/capric triglyceride, and furthermore advantageously the proportion of caprylic/capric triglyceride is at least 90% by weight based on the total weight of all added oils. It is furthermore advantageous when the proportion by weight of the fish eggs to the added oil phase during the homogenization is from 1:0.1 to 1:1 and in particular from 1:0.2 to 1:0.5. If water is added for the homogenization, the proportion by weight of the fish eggs to the aqueous phase formed by addition of water is from 1:10 to 1:1, preferably from 1:8 to 1:2 and particularly preferably from 1:5 to 1:3.
As regards the aqueous caviar extract, it is preferable when, in addition to the water, at least one oil, advantageously caprylic/capric triglyceride, is additionally added during the homogenization. In this case, there is a separation of the lipophilic and hydrophilic constituents of the homogenizate. Correspondingly, predominantly hydrophilic constituents of the homogenizate are extracted during the extraction of the water phase. In this process it is advantageous when the added oil for homogenization contains at least caprylic/capric triglyceride, and furthermore advantageously the proportion of caprylic/capric triglyceride is at least 90% by weight based on the total weight of all added oils. It is furthermore advantageous when the proportion by weight of the fish eggs to the added oil phase during the homogenization is from 1:0.1 to 1:1 and in particular from 1:0.2 to 1:0.5. The proportion of the fish eggs to the aqueous phase is advantageously from 1:10 to 1:1, preferably from 1:8 to 1:2 and particularly preferably from 1:5 to 1:3. It is advantageous per se when the aqueous caviar extract is free of glycols, or the proportions of glycol represent less than 10% by weight based on the total weight of the extract. Advantageously, no glycol is added during or for the homogenization and extraction.
As regards the glycolic caviar extract, it is preferable when propylene glycol is added during the homogenization. In addition to propylene glycol, it is furthermore advantageous when water is also added. The proportion of propylene glycol to water is advantageously from 20:1 to 1:1, preferably 12:1 to 2:1 and particularly preferably 10:1 to 5:1. In this case, constituents of the homogenizate, which are possibly insoluble in pure water, are dissolved in the glycolic solution. After the homogenization, the glycolic phase is extracted. It is furthermore advantageous when the proportion by weight of the fish eggs to the added glycol, in particular to propylene glycol, is from 1:0.1 to 1:100 and in particular from 1:0.2 to 1:20 and in particular 1:0.5 to 1:10.
The active ingredient composition possibly varies depending on the extraction process described.
Advantageously, in the above embodiment the ratio by weight of the lipophilic caviar extract to the aqueous caviar extract is from 50:1 to 1:10, preferably 30:1 to 1:1 and particularly preferably 15:1 to 5:1.
Advantageously, in the above embodiment the ratio by weight of the lipophilic caviar extract to the glycolic caviar extract is from 50:1 to 1:50, preferably 20:1 to 1:20 and particularly preferably 10:1 to 1:10.
In addition to caviar extract, the active ingredient combination according to the invention comprises at least mannose phosphate and/or sodium mannose phosphate.
It is particularly preferable when the sodium mannose phosphate present is sodium mannose 6-phosphate. This is commercially available under the name Sodium mannose 6-phosphate from Sigma Aldrich.
It is likewise preferable when the mannose phosphate present is mannose 6-phosphate.
Advantageously, the ratio by weight of the entirety of the caviar extracts according to the invention to mannose phosphate and/or sodium mannose phosphate is from 200:1 to 1:50, preferably 100:1 to 1:10, preferably from 50:1 to 1:1 and particularly preferably from 30:1 to 2:1.
Advantageously, the ratio by weight of the entirety of the caviar extracts according to the invention to mannose 6-phosphate and/or sodium mannose 6-phosphate is from 200:1 to 1:50, preferably 100:1 to 1:10, preferably from 50:1 to 1:1 and particularly preferably from 30:1 to 2:1.
It is additionally advantageous according to the invention when the active ingredient combination comprises mannose. Advantageously, the ratio by weight of the entirety of the caviar extracts according to the invention to mannose is from 200:1 to 1:50, preferably 100:1 to 1:10, preferably from 50:1 to 1:1 and particularly preferably from 30:1 to 2:1.
It is furthermore advantageous when sodium mannose phosphate and/or mannose phosphate are used together with propane-1,2,3-triol. Accordingly, propane-1,2,3-triol is advantageously present.
The active ingredient combination according to the invention is advantageously used in a very wide range of cosmetic preparations. These are likewise in accordance with the invention.
The cosmetic preparations according to the invention may be present in the customary cosmetic preparation presentation forms, preferably as gel, O/W emulsion, W/O emulsion, W/O/W emulsion, O/W/O emulsion, microemulsion and cosmetic stick.
The cosmetic preparations according to the invention may be present preferably as emulsion, ointment, foundation, toner, aqueous solution, cream, gel, powder, mask, foam preparation and aerosol preparation.
The active ingredient combination according to the invention is advantageously present in cosmetic preparations in proportions of from 0.01% to 5% by weight, preferably from 0.02% to 4% by weight and particularly preferably from 0.05% to 3% by weight, based on the total weight of the cosmetic preparation.
Cosmetic preparations which are applied to the facial skin for daily care are usually formulated as emulsions. Emulsions are generally understood to mean heterogeneous systems which consist of two liquids which are immiscible or miscible only to a limited extent, one of the two liquids being dispersed in the form of very fine droplets in the other liquid. With the naked eye, an emulsion appears homogeneous. If the two liquids are water and oil, and the oil is present as finely distributed droplets in the water, then this is an oil-in-water emulsion (O/W emulsion). On the other hand, if the water is present as finely distributed droplets in the oil, then this is a water-in-oil emulsion (W/O emulsion).
It is particularly advantageous according to the invention when the cosmetic preparation is in the form of an O/W emulsion.
Emulsifiers serve to stabilize emulsions. Stabilization in this context means that the phase separation of the emulsion is prevented or delayed. Accordingly, stable emulsions can be produced by using appropriately selected emulsifier systems.
Emulsifiers are molecules with a polar, hydrophilic structural element and a nonpolar, lipophilic structural element. In general, such molecules can be defined by the HLB value (dimensionless number between 0 and 20) which indicates whether a preferential water or oil solubility is present. Water-in-oil emulsifiers (W/O emulsifiers) usually have an HLB value in the range from 3 to 8. Accordingly, W/O emulsifiers promote the stabilization of an aqueous phase which is present suspended in an oil phase. Oil-in-water emulsifiers (O/W emulsifiers) have an HLB value of greater than 8 to 18. These promote the stabilization of an oil phase which is present suspended in an aqueous phase.
If the cosmetic preparation is present as an oil-in-water emulsion, it is advantageous if the cosmetic preparation contains at least one O/W emulsifier with an HLB value in the range from greater than 8 to 18. O/W emulsifiers to be advantageously selected can be found for example in the following list:
In the above list, the abbreviation EO stands for ethylene oxide and PEG stands for polyethylene glycol.
According to the invention, such an O/W emulsion may advantageously also contain W/O emulsifiers, where the ratio of the O/W emulsifiers to the W/O emulsifiers, taking into account the respective HLB values, should be selected such that an O/W emulsion is formed. A known mixture of O/W emulsifiers and W/O emulsifiers is the commercial product Arlacel 170 from Croda containing Glyceryl Stearate and PEG-100 Stearate, the ratio of the two substances being chosen such that an overall HLB of approximately 11 results.
The cosmetic preparation according to the invention advantageously additionally comprises oils selected from the group of lecithins and fatty acid triglycerides, namely the triglycerol esters of saturated and/or unsaturated, branched and/or unbranched alkanecarboxylic acids with a chain length of 8 to 24, especially 12 to 18 carbon atoms. The fatty acid triglycerides may advantageously be selected from the group of synthetic, semisynthetic and natural oils, such as for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grapeseed oil, safflower oil, evening primrose oil, macadamia nut oil and the like.
Furthermore, the cosmetic preparation according to the invention may advantageously comprise oils which are selected from the group of branched and unbranched hydrocarbons and hydrocarbon waxes, especially petroleum jelly (petrolatum), liquid paraffin, squalane and squalene, polyolefins and hydrogenated polyisobutenes. Among the polyolefins, polydecenes are the preferred substances.
Furthermore, the cosmetic preparation according to the invention may advantageously comprise fat and/or wax components from the group of plant waxes, animal waxes, mineral waxes and petrochemical waxes. Favorable according to the invention are candelilla wax, carnauba wax, Japan wax, esparto grass wax, cork wax, guaruma wax, rice germ oil wax, sugar cane wax, berry wax, ouricury wax, montan wax, jojoba wax, shea butter, beeswax, shellac wax, spermaceti, lanolin (wool wax), uropygial fat, ceresin, ozokerite (earth wax), paraffin waxes and microwaxes.
Further advantageous fat and/or wax components are chemically modified waxes and synthetic waxes, such as for example those available under the trade names Syncrowax HRC (glyceryl tribehenate), and Syncrowax AW 1 C (C18-36 fatty acid) from CRODA GmbH, and also montan ester waxes, Sasol waxes, hydrogenated jojoba waxes, synthetic or modified beeswaxes (e.g. dimethicone copolyol beeswax and/or C30-50 alkyl beeswax), polyalkylene waxes, polyethylene glycol waxes, but also chemically modified fats, such as for example hydrogenated plant oils (for example hydrogenated castor oil and/or hydrogenated coconut fatty glycerides), triglycerides, such as for example trihydroxystearin, fatty acids, fatty acid esters and glycol esters, such as for example C20-40 alkyl stearate, C20-40 alkyl hydroxystearoyl stearate and/or glycol montanate.
It may also be advantageous for the purposes of the present invention when the cosmetic preparation contains cyclic, branched and/or linear silicones. The group of the cyclic, branched and/or linear silicones are also referred to, in the context of the present disclosure, as “silicone oils”. Linear silicone oils are described by the INCI name Dimethicone and have a structure according to the formula (I)
(SiR13)—OSiR22—O
x(SiR13) (I)
while branched silicone oils can be described according to the formula (II)
where R1 and R2 can independently be a hydrogen atom, a methyl group, or a linear or branched, saturated or unsaturated hydrocarbon group having 3 to 30 carbon atoms, and where x, y and z are independently integers in the range from 0 to 60 000. Cyclic silicones are known under the INCI name Cyclomethicone.
It is advantageous in this case if the proportion by weight of the silicone oils in the cosmetic preparation is 3% by weight to 10% by weight, based on the total weight of the cosmetic preparation.
Furthermore, it is an advantageous particular feature of the cosmetic preparation that the total proportion of the oil phase in the O/W emulsion is 2% to 30% by weight, preferably 5% by weight to 25% by weight and particularly preferably 8% by weight to 22% by weight, based on the total weight of the cosmetic preparation. The silicone oils also belong to the oil phase of the cosmetic preparation. Emulsifiers by definition do not belong to the oil phase of the cosmetic preparation according to the invention.
It is moreover advantageous when the total proportion of water in the cosmetic preparation according to the invention is 50% by weight to 95% by weight, preferably 60% by weight to 80% by weight, based on the total weight of the cosmetic preparation.
It is further advantageous when the cosmetic preparation contains one or more rheology modifiers. Rheology modifiers to be chosen with preference are selected from the group of the following INCI substances:
Particular preference is given to selecting the rheology modifiers from the group of the substances known under the INCI names Carbomer, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Polyacrylate, Hydroxyethyl Acrylates/Sodium Acryloyldimethyl Taurate Copolymer and Ammonium Acryloyldimethyltaurate/VP Copolymer.
The total proportion of these rheology modifiers, in particular the total proportion of the rheology modifiers identified above as preferred, is advantageously 0.05% to 5% by weight, preferably from 0.1% to 2.5% by weight, based on the total weight of the cosmetic preparation. Moreover, it is particularly advantageous when, in addition to the substances mentioned above as particularly preferred, tapioca starch is present in a proportion of up to 3.5% by weight, based on the total weight of the cosmetic preparation.
Furthermore, it is advantageous when the ratio by weight of all rheology modifiers according to the invention present to the oil phase present is 1:1 to 1:30, preferably 1:2 to 1:28, particularly preferably 1:20 to 1:27. Such cosmetic preparations according to the invention have a surprisingly advantageous creaminess and are not perceived by the consumer as being crumbly or too oily and too liquid.
It is advantageous according to the invention when the cosmetic preparation according to the invention contains cetyl alcohol, stearyl alcohol or a mixture of cetyl alcohol and stearyl alcohol.
If the cosmetic preparation contains cetyl alcohol, stearyl alcohol or a mixture of cetyl alcohol and stearyl alcohol, it is advantageous according to the invention when the total proportion of these substances is from 0.5% to 5.5% by weight, based on the total weight of the cosmetic preparation.
It is moreover advantageous when the cosmetic preparation according to the invention additionally comprises one or more substances selected from the group of ethanol, isopropanol, propylene glycol, propanediol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether and/or diethylene glycol monomethyl or monoethyl ether. It is preferable here when the cosmetic or dermatological preparation contains glycerol and/or propanediol.
It is likewise advantageous to use the cosmetic preparations according to the invention as sunscreens. Accordingly, the preparations for the purposes of the present invention preferably contain at least one UV-A, UV-B and/or broad-spectrum filter substance. The formulations may, although not necessarily, optionally also contain one or more organic and/or inorganic pigments as UV filter substances, where these may be present in the water phase and/or the oil phase.
The preparations according to the present invention may contain at least one room temperature-liquid UV filter substance.
Particularly advantageous room temperature-liquid UV filter substances for the purposes of the present invention are homomenthyl salicylate (INCI: Homosalate), 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (INCI: Octocrylene), 2-ethylhexyl 2-hydroxybenzoate (2-ethylhexyl salicylate, octyl salicylate, INCI: Ethylhexyl Salicylate) and esters of cinnamic acid, preferably 4-methoxycinnamic acid 2-ethylhexyl ester (2-ethylhexyl 4-methoxycinnamate, INCI: Ethylhexyl Methoxycinnamate) and 4-methoxycinnamic acid isopentyl ester (isopentyl 4-methoxycinnamate, INCI: Isoamyl p-Methoxycinnamate), 3-(4-(2,2-bis(ethoxycarbonylvinyl)phenoxy)propenyl)methoxysiloxane/dimethylsiloxane copolymer, which is available for example under the trade name Parsol® SLX from Hoffmann La Roche.
Preferred inorganic pigments are metal oxides and/or other metal compounds that are sparingly soluble or insoluble in water, in particular oxides of titanium (TiO2), zinc (ZnO), iron (e.g. Fe2O3), zirconium (ZrO2), silicon (SiO2), manganese (e.g. MnO), aluminum (Al2O3), cerium (e.g. Ce2O3), mixed oxides of the corresponding metals and blends of such oxides, and also barium sulfate (BaSO4).
For the purposes of the present invention, the pigments may advantageously also be used in the form of commercially available oily or aqueous predispersions. Dispersing aids and/or solubilizers may be added to these predispersions.
The pigments may according to the invention advantageously be surface-treated (“coated”), where for example a hydrophilic, amphiphilic or hydrophobic character is to be formed or retained. This surface treatment may consist in providing the pigments with a thin hydrophilic and/or hydrophobic inorganic and/or organic layer by methods known per se. For the purposes of the present invention, the various surface coatings may also contain water.
Suitable titanium dioxide particles and predispersions of titanium dioxide particles are available under the following trade names from the companies listed:
Advantageous UV-A filter substances for the purposes of the present invention are dibenzoylmethane derivatives, in particular 4-(tert-butyl)-4′-methoxydibenzoylmethane (CAS No 70356-09-1), which is sold by Givaudan under the brand Parsol® 1789 and by Merck under the trade name Eusolex® 9020.
Further advantageous UV filter substances for the purposes of the present invention are:
Particularly advantageous cosmetic preparations for the purposes of the present invention, which feature a high or very high UV-A protection, preferably also contain, in addition to the filter substance(s) according to the invention, further UV-A and/or broad-spectrum filters, in particular dibenzoylmethane derivatives [for example 4-(tert-butyl)-4′-methoxydibenzoylmethane] and/or 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine and/or phenylene-1,4-bis(2-benzimidazyl)-3,3′-5,5′-tetrasulfonic acid bis-sodium salt, each individually or in any desired combinations with one another.
The list of said UV filters which can be used for the purposes of the present invention is of course not intended to be limiting.
The total amount of the filter substances is chosen from the range of from 0.1% to 30% by weight, preferably 0.5% to 10% by weight, in particular 1.0% to 8.0% by weight—based in each case on the total weight of the cosmetic preparations—in order to provide cosmetic or dermatological preparations which protect the hair or the skin from the entire range of ultraviolet radiation.
It is further advantageous when the cosmetic preparation according to the invention comprises at least one further active ingredient for the cosmetic treatment and/or cosmetic prophylaxis of undesired skin pigmentation.
The cosmetic preparations may accordingly also contain further cosmetic adjuvants such as are conventionally used in such preparations, for example further consistency regulators, film formers, stabilizers, fillers, preservatives, fragrances, substances for preventing foaming, dyes, further pigments which have a coloring effect, surface-active substances, softening, moistening and/or moisturizing substances, anti-inflammatory substances, additional active ingredients such as vitamins or proteins, insect repellents, bactericides, virucides, salts, antimicrobial, proteolytic or keratolytic substances or other conventional constituents of a cosmetic formulation such as further alcohols, polyols, foam stabilizers, organic solvents or electrolytes.
To sum up, the present invention provides in particular:
The particulars shown herein are by way of example and for purposes of illustrative discussion of the embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the present invention. In this regard, no attempt is made to show details of the present invention in more detail than is necessary for the fundamental understanding of the present invention, the description making apparent to those of skill in the art how the several forms of the present invention may be embodied in practice.
Unless otherwise indicated, all amounts, proportions and percentages are based on the weight and the total amount or on the total weight of the preparations.
The efficacy of the invention was verified in an ELISA test. ELISA (enzyme-linked immunosorbent assay) is a widespread method for detecting individual proteins. It utilizes the mechanisms of the immune system: If a substance is recognized as foreign by the immune system, the latter forms “antibodies” that bind to the foreign molecule and thus tag it.
To perform the experiments, hypodermis (from mammoplasty operations) from a healthy donor (56 years of age) was used. The hypodermis was prepared and weighed out into approximately 200 mg pieces. The tissue was cultured in a submersed state in defined and serum-free hypodermis tissue culture medium (CB-EM-HYP) in an actively humidified biomedical incubator (Memmert, Germany) at 37° C. and 5% CO2.
Overnight cultivation was followed by substitution with fresh tissue culture medium. Explants were cultivated either in the presence or absence of test samples.
Over a period of 10 days, the medium was replaced daily with freshly supplemented test samples or with normal media without test samples.
After 10 days of treatment, a portion of the tissue samples was processed for the extraction of ECM proteins.
Isolated ECM was subjected to a protein estimation in accordance with the BCA method (Bicinchoninic Acid) (Sigma Aldrich), and ELISAs (Biotechne) corresponding to the antigen collagen1A2 were performed according to the manufacturer's protocol using the same amounts of proteins as were estimated from the BCA assay. A sensitive filter-based microplate reader (Accuris, USA) was used to perform readout. The ELISA results (% difference) were presented as percentage compared to the untreated control with mean value+/−SEM with repetitions in triplicate execution/condition.
The following test samples were investigated:
The following table specifies the use concentrations of the extracts and of mixture D which were used in the comparative experiment against an untreated control.
The measurements performed clearly show that there is an involvement of synergy between the caviar extracts and mannose phosphate. The additions of propylene glycol, glycerol, glycine, water, phenoxyethanol, triglycerides and galactaric acid alone do not show any increase in the expression of collagen I.
The expression of thrombospondin 1 as a result of use was also investigated in the same screening. Compared to a control, the samples comprising the glycolic extract A did not show any increase in the expression of thrombospondin 1 (control 100%, extract A 46%). The same applies for the expression of thrombospondin 1 with the use of the aqueous extract B (65%). When using the lipophilic extract C, an expression of thrombospondin 1 of 299% compared to the control=100% could be achieved. The mixture D exhibited an expression of thrombospondin 1 of 118%. When using the mixture of A, B, C and D (ratios by weight of A/B/C/D: 1/0.1/1/4), a surprisingly strong expression of 360% could be achieved.
All measurement results shown for the mixture A/B/C/D are significantly (p<0.05) different compared to the untreated condition.
Further cosmetic exemplary formulations are listed hereinafter.
| Number | Date | Country | Kind |
|---|---|---|---|
| 22171536.0 | May 2022 | EP | regional |
